Table 5. Subgroup analysis of the prognostic significance of MICA/B.
| Number of studies | Number of patients | HR 95%CI | Overall effect P-value | Subgroup difference p value | I2 | |
|---|---|---|---|---|---|---|
| Cancer type | 0.02 | |||||
| Respiratory system cancers | 3 | 413 | 2.06 (0.86–4.94) | 0.10 | 76% | |
| Digestive system cancers | 5 | 493 | 0.56 (0.39–0.80) | 0.002 | 35% | |
| Gynecologic cancers | 2 | 277 | 0.85 (0.34–2.15) | 0.74 | 49% | |
| Multivariate correction | 0.04 | |||||
| Yes | 8 | 892 | 1.01 (0.54–1.86) | 0.99 | 85% | |
| No | 2 | 291 | 0.41 (0.23–0.76) | 0.004 | 0% | |
| Antibody | 0.95 | |||||
| MICA | 4 | 537 | 0.87 (0.38–1.96) | 0.73 | 85% | |
| MICA/B | 6 | 646 | 0.84 (0.36–1.93) | 0.68 | 85% | |
| Sample size | 0.45 | |||||
| ≤ 100 | 7 | 623 | 0.74 (0.37–1.50) | 0.41 | 86% | |
| > 100 | 3 | 560 | 1.18 (0.44–3.15) | 0.74 | 80% |